A share price of Nurix Therapeutics Inc [NRIX] is currently trading at $14.54, up 4.60%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The NRIX shares have gain 1.89% over the last week, with a monthly amount drifted -19.27%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nurix Therapeutics Inc [NASDAQ: NRIX] stock has seen the most recent analyst activity on December 10, 2024, when BTIG Research initiated its Buy rating and assigned the stock a price target of $35. Previously, BMO Capital Markets started tracking the stock with Outperform rating on December 06, 2024, and set its price target to $35. On October 24, 2024, UBS initiated with a Buy rating and assigned a price target of $35 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $41 on October 11, 2024. Truist started tracking with a Buy rating for this stock on July 31, 2024, and assigned it a price target of $36.
Nurix Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $11.90 and $29.56. Currently, Wall Street analysts expect the stock to reach $32.38 within the next 12 months. Nurix Therapeutics Inc [NASDAQ: NRIX] shares were valued at $14.54 at the most recent close of the market. An investor can expect a potential return of 122.7% based on the average NRIX price forecast.
Analyzing the NRIX fundamentals
Trailing Twelve Months sales for Nurix Therapeutics Inc [NASDAQ:NRIX] were 54.55M which represents -12.37% decline. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at -3.91%, Pretax Profit Margin comes in at -3.54%, and Net Profit Margin reading is -3.55%. To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.54 and Total Capital is -0.37. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.12 points at the first support level, and at 13.69 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.92, and for the 2nd resistance point, it is at 15.29.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Nurix Therapeutics Inc [NASDAQ:NRIX] is 6.46. Further, the Quick Ratio stands at 6.46, while the Cash Ratio is 1.15. Considering the valuation of this stock, the price to sales ratio is 20.23, the price to book ratio is 2.09.
Transactions by insiders
Recent insider trading involved van Houte Hans, Chief Financial Officer, that happened on Mar 03 ’25 when 5825.0 shares were sold. Officer, JOHANNES VAN HOUTE completed a deal on Mar 03 ’25 to buy 5825.0 shares. Meanwhile, Chief Legal Officer Ring Christine sold 5760.0 shares on Jan 31 ’25.
